. Erratum: FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study. J Clin Oncol 2023 Sep 12:JCO2301858. doi: 10.1200/JCO.23.01858.
PMID: 37699171